FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 5 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in Oncology MOST POPULAR Pregnant Mom Had to Fight for a Diagnosis After Finding a... August 2, 2021 Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... May 7, 2021 Happy New Year From Our Team January 4, 2021 Coming together for Zynlonta July 2, 2021 Load more HOT NEWS 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... Holiday Coping and Enjoying EMA Recommends Extension of Indications for Pembrolizumab This Bar of Soap with a Lump Will Help You Remember...
